摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-[(3R,4R)-1-{(2S)-2-[(tert-butoxycarbonyl)amino]-3-methylbutyl}-3,4-dimethylpiperidin-4-yl]phenyl trifluoromethanesulfonate | 1016162-88-1

中文名称
——
中文别名
——
英文名称
3-[(3R,4R)-1-{(2S)-2-[(tert-butoxycarbonyl)amino]-3-methylbutyl}-3,4-dimethylpiperidin-4-yl]phenyl trifluoromethanesulfonate
英文别名
[3-[(3R,4R)-3,4-dimethyl-1-[(2S)-3-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]butyl]piperidin-4-yl]phenyl] trifluoromethanesulfonate
3-[(3R,4R)-1-{(2S)-2-[(tert-butoxycarbonyl)amino]-3-methylbutyl}-3,4-dimethylpiperidin-4-yl]phenyl trifluoromethanesulfonate化学式
CAS
1016162-88-1
化学式
C24H37F3N2O5S
mdl
——
分子量
522.629
InChiKey
ZBAPNOLTUQGRSE-XTQVGHSUSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    6.3
  • 重原子数:
    35
  • 可旋转键数:
    9
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.71
  • 拓扑面积:
    93.3
  • 氢给体数:
    1
  • 氢受体数:
    9

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    3-[(3R,4R)-1-{(2S)-2-[(tert-butoxycarbonyl)amino]-3-methylbutyl}-3,4-dimethylpiperidin-4-yl]phenyl trifluoromethanesulfonate 、 alkaline earth salt of/the/ methylsulfuric acid 、 alkaline earth salt of/the/ methylsulfuric acid 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 作用下, 以 二甲基亚砜 为溶剂, 反应 48.0h, 以96%的产率得到methyl 3-[(3R,4R)-1-{(2S)-2-[(tert-butoxycarbonyl)amino]-3-methylbutyl}-3,4-dimethylpiperidin-4-yl]benzoate
    参考文献:
    名称:
    Synthesis and In Vitro Opioid Receptor Functional Antagonism of Analogues of the Selective Kappa Opioid Receptor Antagonist (3R)-7-Hydroxy-N-((1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic)
    摘要:
    In previous structure-activity relationship (SAR) studies, we identified (3R)-7-hydroxy-N-((1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic, 1) as the first potent and selective K opioid receptor antagonist from the trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine class of opioid antagonist. In the present study, we report the synthesis and in vitro opioid receptor functional antagonism of a number of analogues of 1 using a [S-35]GTP gamma S binding assay. The results from the studies better define the pharmacophore for this class of K opioid receptor antagonist and has identified new potent and selective kappa antagonist. (3R)-7-Hydroxy-N-[(1 S, 2S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl]methyl}-2-methylbutyl]-1,2,3,4tetrahydroisoquinoline-3-carboxamide (3) with a K-e value of 0.03 nM at the kappa receptor and 100- and 793-fold selectivity relative to the mu and delta receptors was the most potent and selective kappa opioid receptor antagonist identified.
    DOI:
    10.1021/jm701344b
  • 作为产物:
    描述:
    三氟甲磺酸酐吡啶 作用下, 以 二氯甲烷 为溶剂, 反应 3.0h, 以450 mg的产率得到3-[(3R,4R)-1-{(2S)-2-[(tert-butoxycarbonyl)amino]-3-methylbutyl}-3,4-dimethylpiperidin-4-yl]phenyl trifluoromethanesulfonate
    参考文献:
    名称:
    Synthesis and In Vitro Opioid Receptor Functional Antagonism of Analogues of the Selective Kappa Opioid Receptor Antagonist (3R)-7-Hydroxy-N-((1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic)
    摘要:
    In previous structure-activity relationship (SAR) studies, we identified (3R)-7-hydroxy-N-((1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic, 1) as the first potent and selective K opioid receptor antagonist from the trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine class of opioid antagonist. In the present study, we report the synthesis and in vitro opioid receptor functional antagonism of a number of analogues of 1 using a [S-35]GTP gamma S binding assay. The results from the studies better define the pharmacophore for this class of K opioid receptor antagonist and has identified new potent and selective kappa antagonist. (3R)-7-Hydroxy-N-[(1 S, 2S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl]methyl}-2-methylbutyl]-1,2,3,4tetrahydroisoquinoline-3-carboxamide (3) with a K-e value of 0.03 nM at the kappa receptor and 100- and 793-fold selectivity relative to the mu and delta receptors was the most potent and selective kappa opioid receptor antagonist identified.
    DOI:
    10.1021/jm701344b
点击查看最新优质反应信息

文献信息

  • Synthesis and In Vitro Opioid Receptor Functional Antagonism of Analogues of the Selective Kappa Opioid Receptor Antagonist (3<i>R</i>)-7-Hydroxy-<i>N</i>-((1<i>S</i>)-1-{[(3<i>R</i>,4<i>R</i>)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic)
    作者:Tingwei Bill Cai、Zhou Zou、James B. Thomas、Larry Brieaddy、Hernán A. Navarro、F. Ivy Carroll
    DOI:10.1021/jm701344b
    日期:2008.3.1
    In previous structure-activity relationship (SAR) studies, we identified (3R)-7-hydroxy-N-((1S)-1-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic, 1) as the first potent and selective K opioid receptor antagonist from the trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine class of opioid antagonist. In the present study, we report the synthesis and in vitro opioid receptor functional antagonism of a number of analogues of 1 using a [S-35]GTP gamma S binding assay. The results from the studies better define the pharmacophore for this class of K opioid receptor antagonist and has identified new potent and selective kappa antagonist. (3R)-7-Hydroxy-N-[(1 S, 2S)-1-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl]methyl}-2-methylbutyl]-1,2,3,4tetrahydroisoquinoline-3-carboxamide (3) with a K-e value of 0.03 nM at the kappa receptor and 100- and 793-fold selectivity relative to the mu and delta receptors was the most potent and selective kappa opioid receptor antagonist identified.
查看更多